The global irritable bowel syndrome treatment market size is
expected to reach USD 3.3 billion by 2026, according to a new report by Grand
View Research, Inc., exhibiting a 10.1% CAGR during the forecast period. Rising
prevalence of target disease and increasing label extension of existing drugs
are likely to accelerate market growth. In addition, growing uptake of drugs
and launch of novel products are anticipated to drive the irritable bowel
syndrome (IBS) treatment market.
IBS is one of the most common gastrointestinal disorders, with the
worldwide prevalence rate usually ranging between 10-15%. Most of the patients
with IBS are under 50 years of age but many older adults suffer as well. The
effect of the condition can vary from mild inconvenience to serious
debilitation. It can control many facets of a patient’s professional,
emotional, and social life. Patients with moderate to severe conditions usually
struggle with symptoms that frequently impair their emotional, physical,
educational, social, and economic wellbeing.
Symptoms can vary and are sometimes contradictory, constipation
can alternate with diarrhea. Long-term symptoms can disturb the patient’s
professional and personal activities, and usually limits an individual’s
potential.These factors further increase the need for irritable bowel syndrome
treatment, which enable patients to go on with their regular life.
Around 40% patients have mild IBS, 35% have moderate IBS, and 25%
have severe IBS. A significant number of people cannot distinguish IBS
symptoms; it is still one of the most common disorders diagnosed by physicians.
Not everyone with IBS symptoms pursues treatment for the same. Though, there
are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in
U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.
Browse full research report on Irritable Bowel Syndrome
Treatment Market: https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market
Further key findings from the report suggest:
- IBS-C
was the largest revenue generating segment by type in 2018 due to growing
prevalence and increasing uptake of drugs such as Linzess/Constella and
Amitiza
- Linzess/Constella
led the global IBS treatment market by product in 2018 due to increasing
adoption of the product in major regions such as U.S., Germany, U.K.,
Italy, Spain, and Japan
- North
America was estimated to be the largest revenue generating region in 2018,
followed by Europe. Major factors contributing to its dominant share are
presence of key market players, high patient awareness, strong presence of
novel products, and well-established healthcare infrastructure
- Europe
is projected to be the fastest growing region over the forecast period.
Rising commercialization of products and presence of a large target
population are driving the IBS treatment market
- Some
of the major players are Allergan; Ironwood Pharmaceuticals, Inc.;
Astellas Pharma, Inc.; AstraZeneca; Takeda Pharmaceutical Company Limited;
Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Ardelyx; and
Bausch Health
- Players
have bene adopting strategies such as product extension, product
development, regional expansion, and mergers and acquisitions to increase
their market share. Bausch Health acquired Salix Pharmaceuticals in April
2015 to expand its portfolio with a focus on gastrointestinal drugs.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market/request/rs1
Grand View Research has segmented the IBS treatment market based
on type, drug, and region:
Irritable Bowel Syndrome Treatment Type Outlook (Revenue, USD
Million, 2014 - 2026)
- IBS-C
- Linzess/Constella
- Amitiza
- Others
- IBS-D
- Xifaxan
- Viberzi
- Others
Irritable Bowel Syndrome Treatment Product Outlook (Revenue, USD
Million, 2014 - 2026)
- Xifaxan
- Linzess/Constella
- Viberzi
- Amitiza
- Others
Irritable Bowel Syndrome Treatment Regional Outlook (Revenue, USD
Million, 2014 - 2026)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- Middle
East & Africa
- South
Africa
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
No comments:
Post a Comment